Expression of VEGF-A/VEGFR-2 pathway in feline oral squamous cell carcinoma in vitro and anti-tumour effect of Bevacizumab in a xenograft model.

Bevacizumab demonstrates anti-tumor activity against feline oral squamous cell carcinoma in vitro and in vivo.

This study investigated the vascular endothelial growth factor A (VEGF-A) and VEGF receptor 2 (VEGFR-2) signaling pathway in feline oral squamous cell carcinoma (FOSCC) and evaluated bevacizumab, a monoclonal antibody targeting VEGF-A, as a potential therapeutic agent. Using three FOSCC cell lines (SCCF1, SCCF2, SCCF3), researchers demonstrated expression and activation of the VEGF-A/VEGFR-2 axis under both basal and serum-starved conditions, indicating functional autocrine signaling. In vitro treatment with bevacizumab (50-100 µg/mL) inhibited VEGFR-2 activation and downstream AKT signaling. In vivo xenograft studies using luciferase-expressing SCCF3 cells showed that bevacizumab (5 mg/kg, twice weekly) significantly suppressed tumor growth. These findings suggest that VEGF-A/VEGFR-2 pathway targeting represents a viable therapeutic strategy for aggressive feline oral squamous cell carcinomas, offering potential for translational application of monoclonal antibody-based molecular targeted therapy in veterinary oncology.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.